trending Market Intelligence /marketintelligence/en/news-insights/trending/g7gn7dzuxix9y9-n59uvja2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Xbrane, BioAvenir enter sales, marketing agreement for Spherotide in Israel

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program


Xbrane, BioAvenir enter sales, marketing agreement for Spherotide in Israel

Xbrane Biopharma AB (publ) signed a distribution agreement with BioAvenir for marketing and sales of Spherotide in Israel.

Xbrane will receive 1 million Swedish kronor as a license fee, divided into up-front and milestone payments until product launch. Both companies will share the profits from the sales of the drug in Israel, where it is expected to launch in 2020.

The drug's launch in Israel is subject to market authorization from Israel's Ministry of Health.

Spherotide is used primarily in the treatment of prostate cancer, endometriosis and uterine fibroids. For the Israeli market, it will be produced in Xbrane's production facility in Italy for resale to BioAvenir.

Xbrane estimates, based on expected price and penetration, that Spherotide has a sales potential of about 5 million Swedish kronor annually in Israel.

BioAvenir is a privately held company specializing in licensing, registering, and commercializing pharmaceuticals and special products in Israel.

As of Dec. 20, US$1 was equivalent to 9.37 Swedish kroner.